Keywords
Curation
Ncbi
Racine
Curation
Checkpoint
Ncbi
Racine
Ncbi
Exploration
Accueil
Racine
Racine

Movement Disorders (revue) - Curation (Ncbi)

Index « Keywords » - entrée « Neuroprotective Agents (adverse effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Neuroprotective Agents (administration & dosage) < Neuroprotective Agents (adverse effects) < Neuroprotective Agents (pharmacology)  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 12.
Ident.Authors (with country if any)Title
000018 (1999) H D Rosas [États-Unis] ; W J Koroshetz ; B G Jenkins ; Y I Chen ; D L Hayden ; M F Beal ; M E CudkowiczRiluzole therapy in Huntington's disease (HD).
000A49 (2003) Melih Vural [Turquie] ; Sibel Ozekmekçi ; Hülya Apaydin ; Attila AltinelHigh-dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophy.
000C97 (2004) Susan Hollán [Hongrie] ; Lászl Vécsei ; Kálmán MagyarAdverse effects of dopamine potentiation by long-term treatment with selegiline.
001567 (2006) Todd B. Sherer [États-Unis] ; Brian K. Fiske ; Clive N. Svendsen ; Anthony E. Lang ; J William LangstonCrossroads in GDNF therapy for Parkinson's disease.
001816 (2006) Tanya Y. Gurevich [Israël] ; Herzel Shabtai ; Amos D. Korczyn ; Ely S. Simon ; Nir GiladiEffect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
001930 (2007) Norman ReynoldsRevisiting safety of minocycline as neuroprotection in Huntington's disease.
003507 (2011) Alfonso Fasano ; Alessandro Di Matteo ; Carmine Vitale ; Giovanna Squintani ; Laura Ferigo ; Federica Bombieri ; Gabriella Santangelo ; Marianna Amboni ; Paolo Barone ; Michele TinazziReversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy.
003A96 (2013) Fanny Duval [France] ; Olivier Flabeau ; Julien Razafimahefa ; Umberto Spampinato ; François TisonEncephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome.
004A96 (1996) K. Kieburtz [États-Unis] ; A. Feigin ; M. Mcdermott ; P. Como ; D. Abwender ; C. Zimmerman ; C. Hickey ; C. Orme ; K. Claude ; J. Sotack ; J T Greenamyre ; C. Dunn ; I. ShoulsonA controlled trial of remacemide hydrochloride in Huntington's disease.
004C24 (1996) A. Ikeda [Japon] ; H. Shibasaki ; K. Tashiro ; Y. Mizuno ; J. KimuraClinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group.
004F42 (1998) C W Olanow [États-Unis] ; C. Mytilineou ; W. TattonCurrent status of selegiline as a neuroprotective agent in Parkinson's disease.
005024 (1998) S. Fahn [États-Unis] ; K E Clarence-Smith ; T N ChaseParkinson's disease: neurodegenerative mechanisms and neuroprotective interventions--report of a workshop.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Neuroprotective Agents (adverse effects)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Neuroprotective Agents (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Neuroprotective Agents (adverse effects)
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024